Grail, Inc. (GRAL) fundamentals score
Grail is an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. It believes screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
Services-Medical Laboratories · Healthcare · Listed on NASDAQ
Overall: 5.2 out of 10, Mixed fundamentals
- Growth: 6.4/10
- Profitability: 3.3/10
- Financial health: 8.0/10
- Earnings quality: 6.5/10
- Valuation: 1.4/10
Scores are calculated from Grail, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10